BTX - BioTime, Inc.
| Previous close | 2.370 |
| Open | 2.370 |
| Bid | 0.000 x 1200 |
| Ask | 0.000 x 1000 |
| Day's range | 2.360 - 2.410 |
| 52-week range | 2.080 - 3.210 |
| Volume | 127,666 |
| Avg. volume | 349,853 |
| Market cap | 304.495M |
| Beta | 2.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.111 |
| Earnings date | 31 Jul 2018 - 6 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.63 |
- Simply Wall St.•6 days ago
June Fundamental Stock Pick: Forbuild SA (WSE:BTX)
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Forbuild SA (WSE:BTX) due to its excellent fundamentals in more thanRead More...
- Business Wire•9 days ago
AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
Following the sale, BioTime owns approximately 80.6% of AgeX’s outstanding shares and Juvenescence and its principals owns approximately 7%. “AgeX is positioned to be a leader in developing therapeutics targeting some of the most compelling opportunities in the commercial market associated with aging,” said Dr. Greg Bailey, M.D. CEO of Juvenescence.
- Business Wire•12 days ago
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the proposed distribution of some or all of BioTime’s shares of AgeX Therapeutics, Inc. (“AgeX”) common stock, on a pro rata basis, to BioTime’s shareholders of record as of a date to be determined.
- Business Wire•15 days ago
AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced the appointment of financial expert, commentator, and bestselling author John F.
- Business Wire•21 days ago
BioTime to Present at the 8th Annual LD Micro Invitational
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th Annual LD Micro Invitational Conference on Monday, June 4, 2018 at 1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
- Business Wire•22 days ago
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4.
- Business Wire•22 days ago
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million. OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4.
- Business Wire•27 days ago
BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen®, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter. “The addition of these two leading U.S. clinical trial sites is in addition to our current two sites in California.
- Business Wire•last month
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. , today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will deliver a keynote presentation at World Advanced Therapies & Regenerative Medicine Congress, May 16-18 in London.
- Business Wire•last month
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
ALAMEDA, Calif.--(BUSINESSWIRE)-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc . (NYSE American: BTX), today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also ...
- Associated Press•last month
BioTime: 1Q Earnings Snapshot
The Alameda, California-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs, were 9 cents per share. The biotechnology company posted revenue of $701,000 in ...
- Business Wire•last month
BioTime Reports First Quarter Results and Recent Corporate Accomplishments
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments.
- Business Wire•2 months ago
AgeX Announces NIH Grant Award
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The grant provides funding for continued development of the company’s technologies for treating stroke. “In this highly-competitive environment, this grant is a validation of our core technology,” commented Michael D. West, Ph.D., CEO of AgeX.
- Business Wire•2 months ago
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen® for dry-AMD, was presented at the Association for Research in Vision and Ophthalmology meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii.
- Business Wire•2 months ago
BioTime to Announce First Quarter 2018 Results on May 10, 2018
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.S.
- Business Wire•2 months ago
Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii.
- Zacks•2 months ago
BioTime (BTX): Moving Average Crossover Alert
BioTime, Inc. (BTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- Business Wire•2 months ago
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit.
- Business Wire•3 months ago
BioTime Announces Cash Sale of Ascendance Biotechnology
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.
- Associated Press•3 months ago
BioTime reports 4Q loss
On a per-share basis, the Alameda, California-based company said it had a loss of 58 cents. Losses, adjusted for non-recurring costs, came to 8 cents per share. The biotechnology company posted revenue ...
- Business Wire•3 months ago
BioTime Reports Fourth Quarter and Fiscal 2017 Results
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.
- Zacks•3 months ago
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.
- Business Wire•3 months ago
BioTime Submits CE Mark Application for European Approval of Renevia®
BioTime, Inc. , a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia® in Europe.
- Business Wire•3 months ago
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
BioTime, Inc. , a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial.
- Business Wire•4 months ago
BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
BioTime, Inc. , a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S.
